Intended for healthcare professionals

Letters UK deal over inclisiran

Do PCSK9 inhibitors do anything more than reduce LDL cholesterol?

BMJ 2020; 368 doi: (Published 24 March 2020) Cite this as: BMJ 2020;368:m1159
  1. Andrew N Bamji, retired consultant rheumatologist
  1. Rye TN31 7ES, UK
  1. bamji{at}

Byrne and colleagues point out the lack of reliable evidence on cardiovascular risk with inclisiran, and the omens are not good.1

Inclisiran undoubtedly has a marked lowering effect on low density lipoprotein (LDL) cholesterol, which was first reported in 2017. But does a 30-50% reduction in LDL cholesterol translate to a 30-50% reduction in cardiovascular risk? Almost certainly not.

The inclisiran results include an “exploratory cardiovascular endpoint” (a secondary …

View Full Text

Log in

Log in through your institution


* For online subscription